Login
Create An Account
Login
Create An Account
Search
View All
View All
All Categories
Critical Care, Anaesthetics & Emergency Medicine
Gerontology, Lifestyle Disease & Healthy Aging
Infectious Diseases, Vaccines & Antimicrobials
Ophthalmology
Paediatrics & Neonatology
Healthcare Alerts
Disease Outbreak Resources »
Cholera Outbreak Resources & Updates
The Medical Week in Review | Archive
Terms and Conditions of Use
What's the Diagnosis
Home
Contact Us
Search
Reset
Novel Drugs & Emergent Therapeutics Archive 2024
View Novel Drugs & Emergent Therapeutics 2023 Archive
View Novel Drugs & Emergent Therapeutics 2024 Archive
Currently reading
Novel Drugs & Emergent Therapeutics Archive 2024
Date
Indication
Company
Drug / Device
Status
Title & Link
15/04/2024
IgA Nephropathy
Novartis
Fabhalta® (iptacopan)
Phase 111
Novartis presents the results of the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan) for the treatment of patients with IgA nephropathy (IgAN)
4
/04/2024
CABP/SAB
Basilea Pharmaceutica International
Zevtera (ceftobiprole medocaril sodium)
Approved
FDA Approves New Antibiotic for Three Different Uses
Rate
Viewed
Bookmark
Print
Rating
Rating Value
Most Viewed Articles
All That Remains: A Renowned Forensic Scientist on Death, Mortality, and Solving Crimes
Nov 17, 2023
MNG004-World Health Organisation requests information from China regarding outbreak of respiratory diseases
Nov 23, 2023
CDC Flags BA.2.86 COVID Variant
Dec 04, 2023
Rate This Media
×
1
2
3
4
5
Home
Contact Us
Log in
Powered by eLecture, a VisualLive Solution
© Copyright 2024
Terms of Use
Disclaimer
We use cookies to track how our site is used, but do not store any personal data. For more information, please review our Terms and Conditions.
I agree